<h1>Orchid Pharma Ltd Board Approves Issuance of Shares under Amalgamation Scheme</h1>
Orchid Pharma Ltd has announced that its Board of Directors approved the issuance and allotment of equity shares as part of a scheme of Amalgamation involving Dhanuka Laboratories Limited. The approval was made during a meeting held on August 01, 2026.
The company approved the allocation of 4,45,86,052 fully paid up equity shares, each at Rs. 10, to eligible shareholders of Dhanuka Laboratories Limited (the Amalgamating Company). These shares were allotted following the scheme of Amalgamation and to shareholders as of the record date July 23, 2026.
The newly issued shares are set to be listed and traded on both BSE Limited and National Stock Exchange of India Limited, and they will rank pari passu with Orchid Pharma Ltd's existing equity shares.
Following this allotment and the cancellation of cross holding of Dhanuka Laboratories Limited, the company’s paid up share capital has been updated. The total paid up share capital now stands at Rs. 59,88,52,000, which is divided into a total of 5,98,85,200 shares of Rs. 10 each.
Key details regarding the equity issuance are summarized below:
| Particulars | Details |
|---|---|
| Type of securities proposed to be issued | Equity Shares |
| Type of issuance | Allotment pursuant to scheme of Amalgamation |
| Total number of shares proposed to be issued | 4,45,86,052 equity shares ranking pari passu to existing equity shares |
ORCHPHARMA Stock Price Movement
On Friday, shares of Orchid Pharma Limited slipped by 0.92% to close at ₹986.55, shedding ₹9.25 from the previous day's close. The stock saw a volume of 29,849 shares traded on that day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.